Catalyst Wire Dossier Catalyst Wire Dossier
EMA approval · 2026-07-08

EMA Authorised: Ebixa (memantine hydrochloride) — H. Lundbeck A/S

View source ↗

Summary

Memantine hydrochloride (Ebixa) has been authorised for use in Alzheimer disease in the European Union.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Ebixa (memantine hydrochloride)

Snippet

Status: Authorised. Therapeutic area: Alzheimer Disease. MAH: H. Lundbeck A/S. Decision date: 08/07/2026